After a month where bad news seemingly poured in from every corner of the world, investors limped into this afternoon looking for signs of reassurance from the Federal Reserve meeting. What they got was a mixed bag.
Leaving its QE3 gun resting squarely in its holders, the Fed instead opted to take a more staid approach, announcing plans to continue with its Operation Twist through at least the end of the year. Operation Twist, in which it buys long-time-horizon Treasury bonds and sells short-term Treasury bills, is aimed to drive down long-term interest rates and kickstart what's becoming an increasingly moribund recovery. The Fed also firmly stated that it's prepared to break out its monetary bazooka should it deem such action necessary further down the road.
Thanks, but no, thanks
Stocks moved sharply south in their initial reaction, only to regain composure and end largely where we saw them going into the Fed meeting -- flat. Looking at the tape, the Dow Jones Industrial Average
- Shares of consumer-goods conglomerate Procter & Gamble
tumbled 3% as the company lowered guidance for its current quarter. Equally dismal, the company also reduced its estimates for its current fiscal year as well as a result of weakening consumer demand and adverse foreign exchange rates. (NYSE: PG)
rose 8.3% ahead of a ruling on its diet drug lorcaserin. The Food and Drug Administration is expected to disclose its decision by June 27. The stock is up more than 400% since the start of the year. (Nasdaq: ARNA)
- Shares of Molycorp
surged more than 10% only to settle 8% higher on the day. News today broke that China held lower amounts of rare-earth material than originally thought, which of course implies demand from commodity companies like Molycorp. (NYSE: MCP)
The road ahead
The key takeaway from today's announcement is that the Fed showed it's committed to keeping America's recovery rolling. That's just one reason that, despite potential headwinds, the future will indeed be made in America. Count on it. In fact, the Fool details one stock poised to win big time in our new research report, which you can grab by clicking here today.
Motley Fool newsletter services have recommended buying shares of Procter & Gamble. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Does a Strong Start Make 2018 a Sure Winner for Stocks?
Find out whether the so-called "January effect" is real.
Meet the 2018 Dogs of the Dow
Learn the basics of this simple dividend-investing strategy.
The Dow's Worst Day in 2017
Even with big gains, there were some scary times for the average.